Akt kinase is activated by transforming growth factor-β1 (TGF-β) in diabetic kidneys, and has important roles in fibrosis, hypertrophy and cell survival in glomerular mesangial cells 1-11 . However, the mechanisms of Akt activation by TGF-β are not fully understood. Here we show that TGF-β activates Akt in glomerular mesangial cells by inducing the microRNAs (miRNAs) miR-216a and miR-217, both of which target PTEN (phosphatase and tensin homologue), an inhibitor of Akt activation. These miRNAs are located within the second intron of a non-coding RNA (RP23-298H6.1-001). The RP23 promoter was activated by TGF-β and miR-192 through E-boxregulated mechanisms, as shown previously 3 . Akt activation by these miRs led to glomerular mesangial cell survival and hypertrophy, which were similar to the effects of activation by TGF-β. These studies reveal a mechanism of Akt activation through PTEN downregulation by two miRs, which are regulated by upstream miR-192 and TGF-β. Due to the diversity of PTEN function 12,13 , this miR-amplifying circuit may have key roles, not only in kidney disorders, but also in other diseases.
Diabetic nephropathy is a major complication of diabetes. Its key features include glomerular mesangial expansion, hypertrophy and accumulation of extracellular matrix (ECM) proteins, such as collagen, in the kidney 2,3,7,10,11 . The phosphatidylinositol 3-kinase (PI3K)-Akt pathway is activated in animal models of diabetic nephropathy [4] [5] [6] [7] , and Akt1 -/mice are protected from hyperhexosemia-induced mesangial hypertrophy and ECM accumulation 7 . These results implicate Akt kinase as a key mediator of diabetic nephropathy . Increased expression of TGF-β is observed in renal cells during diabetic nephropathy progression [1] [2] [3] . Activation of the PI3K-Akt pathway by TGF-β 4, 5, [8] [9] [10] has been related to increased ECM protein expression 9,10 , hypertrophy 5 , cell survival and oxidant stress in glomerular mesangial cells 4 . However, the mechanism by which TGF-β activates Akt has not been fully elucidated.
miRNAs are short non-coding RNAs that induce gene silencing, mainly by blocking mRNA translation or promoting mRNA degradation 14, 15 . A number of miRNAs are highly expressed in the kidney 16, 17 . In TGF-βtreated mouse glomerular mesangial cells (MMCs) and in diabetic mouse glomeruli, miR-192 has been shown to be upregulated and to increase collagen type I α2 chain (Col1a2) expression by downregulating Zeb2 (also known as SIP1 or Zfhx1b), an E-box repressor 3 . Another report showed that miR-377 regulates fibronectin expression in diabetic nephropathy 18 . However, the functional roles and regulation of other renal miRs are unclear. Here we show that in MMCs, miR-216a is upregulated by TGF-β in a dose-and time-dependent manner, similarly to miR-192 ( Fig. 1a, b ; Supplementary Information, Fig. S1c, k) 3 . Col1a2 was induced in parallel. miR-216a levels were also increased in renal glomeruli isolated from type 1 (streptozotocin, STZ, -injected) and type 2 (db/db) diabetic mice relative to their controls (C57BL/6 and db/+, respectively; Fig. 1c ).
miR-216a lies in the second intron of a non-coding RNA (RP23-298H6.1-001, RP23) located in the mouse chromosome 11 (miRBase, http://microrna.sanger.ac.uk; Fig. 1d ; Supplementary  Information, Fig. S2a ) 19 . RP23 levels were also increased by TGF-β in MMCs ( Fig. 1a, b ; Supplementary Information,Fig. S1b, j) . Interestingly, another miRNA, miR-217, was present in the same intron, 6.6 kb downstream of miR-216a ( Fig. 1d ). Indeed, miR-217 levels were increased in TGF-β-treated MMCs (Fig. 1a, b ; Supplementary Information, Fig. S1d, l) , and in the glomeruli of diabetic mice (Fig. 1c ). Therefore, miR-216a and miR-217 were expressed along with RP23 and induced by diabetic conditions or TGF-β.
Next, the RP23 promoter region was examined. We focused on 5'-CAGA-3' repeats (Smad binding elements) and E-boxes (5'-CAXXTG-3'), due to their function in TGF-β response 3, 20 . Several 5'-CAGA-3' repeats and E-boxes were found in the RP23 upstream region, especially from -5 kb to -2 kb (Fig. 1e ). Upstream fragments of the RP23 gene were cloned into a luciferase reporter construct, pGL4-Luc, and transfected into MMCs. The longest construct, RP23-4.8 kb-Luc, had the lowest basal activity, but showed a significant response to TGF-β ( Fig. 1f ). RP23-3.5 kb-Luc had intermediate basal activity and also responded to TGF-β. The shortest construct, RP23-2.7 kb-Luc, had highest basal activity, but no TGF-β response. The -4.8 to -2.7 kb region seemed to have negative elements for basal activity, and positive elements for TGF-β-response. To identify the elements, partial fragments of this region were cloned into pGL3P-Luc. Whereas RP23-3.5-2.7 kb-Luc responded to TGF-β, neither RP23-4.8-3.5 kb-Luc nor pGL3P alone did ( Fig. 1g ). Deletion of two or three upstream E-boxes from -3.5 to -2.7 kb did not alter TGF-β effects ( Fig. 1g ). However, mutation of the most proximal E-box completely abrogated the TGF-β response, confirming that E-boxes within -3.5 to -2.7 kb are essential for the TGF-β response in MMCs. E-boxes are negatively regulated by Zeb1 and Zeb2 (refs 3, 21, 22) . miR-192 upregulates Col1a2 by targeting Zeb2 (ref. 3) . In time course experiments, TGF-β induced a significant increase in miR-192 by 30 min, whereas induction of RP23, miR-216a and miR-217 required 1 h ( Fig. 1b ; Supplementary Information, Fig. S1i -l), suggesting that miR-192 may upregulate RP23, miR216a and miR-217. Zeb1 and Zeb2 were reduced at 1 h ( Fig. 1b ; Supplementary Information, Fig S1m, n) . Transfection of MMCs with a miR-192 mimic or Zeb2 siRNA (short interfering RNA) significantly decreased Zeb2 levels and increased the expression of RP23, miR-216a and miR-217 ( Fig. 1h , i) as well as RP23-3.5-2.7k-Luc activity ( Fig. 1j ). By inhibiting Zeb2, miR-192 relieves the repression of RP23 (as well as miR-216a and miR-217) through its upstream E-boxes, similarly to collagen induction by TGF-β 3 . The initial induction of miR-192 by TGF-β may subsequently increase RP23, miR-216a and miR-217.
Transcription factor E3 (TFE3) is a positive regulator of E-boxes 20, 23 . Ectopic expression of Tfe3 significantly increased RP23-3.5-2.7 kb promoter activity ( Supplementary Information, Fig. S2b ). Conversely, knockdown of Tfe3 by shRNAs (short hairpin RNAs) 23 significantly decreased reporter activity ( Supplementary Information, Fig. S2c ). Chromatin immunoprecipitation (ChIP) assays revealed that Tfe3 occupancy at the RP23-3.5-2.7 kb region was increased by TGF-β, whereas Zeb1 occupancy was decreased (Supplementary Information, Fig. S2d, e ). E-box regulators may have key roles in the transcription of RP23, miR-216a and miR-217 through TGF-β collaborating with Smads 20 ( Supplementary Information, Fig. S2i ).
Genomic structures of miR216a and miR-217 are conserved from human to mouse, rat and zebrafish 19, 24, 25 . As in the mouse genome, in the human genome miR-216a and miR-217 also lie in the second intron of a non-coding RNA (DA732292, DA73) in chromosome 2 and 5'-CAGA-3' and E-box clusters were found in the human DA73 promoter (-7 kb upstream; Supplementary Information, Fig. S2f ). The -7.3 to -6.5 kb upstream region of DA73 was cloned into pGL3P and transfected into MMCs or human embryonic kidney (HEK-293) cells. The luciferase activity of this construct was significantly enhanced by TGF-β or miR-192 mimics ( Supplementary Information, Fig. S2g, h) . These results suggest a conserved regulation of miR-216a and miR-217 from mouse to human.
Using miR target predictions (TargetScan, http://www.targetscan.org), we found that PTEN is a potential target of both miR-216a and miR-217 ( Fig. 2a ). PI3K generates PIP3 (phosphatidylinositol-3, 4, 5-triphosphate) from PIP2 (phosphatidylinositol 4,5-bisphosphate), which then activates Akt 12, 13 . PTEN dephosphorylates PIP3 to inhibit Akt activation. PTEN mutations enhance Akt activity in certain cancer cells 12 . Akt activation and decreased Pten are observed in glomerular mesangial cells treated with high glucose or TGF-β 5 . Therefore, PTEN might be a link between TGF-β and Akt activation.
Decreased levels of Pten were confirmed in glomeruli of diabetic db/ db mice ( Fig. 2b-d ) and in MMCs treated with TGF-β or high glucose ( Fig. 2e) . A miR-216a or miR-217 mimic decreased Pten levels in MMCs (to 30~40% of negative control levels; Fig. 2f , g). Simultaneous transfection with these two mimics decreased Pten levels to a greater extent (to ~10% of negative control levels), suggesting an additive effect of these two miRs on Pten downregulation. Despite a significant decrease in Pten protein levels in TGF-β-treated MMCs, no decrease in Pten mRNA levels was observed ( Fig. 1a, b ; Supplementary Information, Fig. S1h, p) , suggesting post-transcriptional reduction of Pten by TGF-β in MMCs.
TGF-β activated Akt (Ser 473 phosphorylation) in MMCs ( Fig. 2h ), consistent with previous reports 4, 5 . A parallel increase in Akt activation in MMCs transfected with miR-216a, miR-217 or both ( Fig. 2i ) further confirmed that miR-216a and miR-217 target Pten in response to TGF-β. To verify whether these miRs target the Pten 3'UTR, luciferase reporters containing Pten 3'UTR (full-length and shorter form with miR-216a and miR-217 target sites) were constructed. Both miR-216a and miR-217 mimics significantly inhibited Pten 3'UTR luciferase activity relative to negative controls, whereas Pten 3'UTR containing mutations at miR-216a and/or miR-217 sites lost this response ( Fig. 2k ; Supplementary Information, Fig. S4a ). Similar inhibition was observed with TGF-β treatment, which induced a decrease in luciferase activity; however, miR-216a and miR-217 inhibitors could override this effect ( Fig. 2l , m; Supplementary Information, Fig. S4b -g). These results confirm that Pten 3'UTR is a target of miR-216a and miR-217.
Transgenic mice with the miR-17-92 cluster had lymphoproliferative diseases due to decreased levels of Pten and Bim, which are targeted by this cluster 26 . They also had enlarged kidney glomeruli, hypercellularity, mesangial expansion and proteinuria (features similar those of diabetic nephropathy). These observations further support the physiological significance of our data that Pten downregulation by miRNAs is an important step in kidney dysfunction.
Next, inhibitors of miR-192, miR-216a and miR-217 were tested to determine the functional relevance of these miRNAs. First, we used MMCs treated with TGF-β, as these cells show features of diabetic nephropathy (Akt activation and ECM accumulation). Inhibitors of miR-216a and miR-217 reversed the effects of TGF-β treatment on Pten and phospho-Akt (P-Akt) levels ( Fig. 3a, b) , as did the miR-192 inhibitor ( Fig. 3c, d ). Moreover, a miR-192 inhibitor reversed the effects of TGF-β on RNA expression of miR-192, RP23, miR-216a, miR-217, Zeb2 and Col1a2 (Fig. 3e ), and attenuated TGF-β-induced RP23 promoter activation ( Fig. 3f ). Therefore, the miR-192 inhibitor blocked key pathological effects of TGF-β, in MMCs, related to diabetic nephropathy (including Col1a2 and Akt activation).
Next, we examined the in vivo consequences of miR-192 inhibition using locked nucleic acid (LNA)-modified oligonucleotides. LNA anti-miRs are potent miR inhibitors even in primates 27 . Marked accumulation of a subcutaneously injected LNA-modified miR-192 inhibitor (anti-miR-192) was observed in mouse kidneys, relative to injected saline ( Fig. 3g-j) . LNA-anti-miR-239b targeting Caenorhabditis elegans miR-239b (similar sequences are not found in mammalian RNAs) was injected as a negative control. LNA-anti-miR-192, but not LNA-anti-miR-239b, significantly inhibited miR-192 levels in renal cortical tissues (Fig. 3k ). The expression of miR-194 was unaffected, indicating the specificity of LNA-anti-miR-192, which also attenuated P-Akt while augmenting Pten levels relative to saline and LNAanti-miR-239b controls (Fig. 3l, m) . Concomitant decreases in RP23, miR-216a, miR-217 and Col1a2 levels (but not miR-194 or cyclophilin A, CypA) were observed (Fig. 3n ). These in vivo data further support miR-192 as a master regulator of other related miRNAs, and the therapeutic potential of anti-miR-192 for diabetic nephropathy.
The possible cell-type differential effects of miRs should however be considered while designing such therapies. Next, the biological significance and downstream consequences of Akt activation by this miR circuit were evaluated. Phosphorylation of Akt targets, FoxO3a, mTOR and GSK3β, which are associated with cell survival and hypertrophy [4] [5] [6] 28 , was induced by miR-192 and miR-216a + miR-217 mimics as well as TGF-β ( Fig. 4a-d) . Interestingly, phosphorylation of these proteins by TGF-β was blocked or attenuated by inhibitors of these miRNAs ( Fig. 4a-d ), suggesting that this miRNA circuit affects key Akt targets. As Akt-induced phosphorylation of FoxO3a transcription factor promotes its nuclear to cytoplasmic translocation and inactivation, we then tested the effects of the miRNAs in MMCs transfected with a vector expressing FoxO3a-GFP 4 (GFP, green fluorescent protein). Serum depletion induced nuclear localization of FoxO3a, whereas TGF-β treatment induced cytoplasmic translocation, presumably due to Akt activation and e a + - FoxO3a phosphorylation (Fig. 4e) , as reported previously 4 . The miR-192 and miR-216a + miR-217 mimics induced a similar cytoplasmic translocation of FoxO3a in serum-depleted MMCs (Fig. 4e) . Conversely, inhibitors of these miRNAs induced nuclear localization of FoxO3a in TGF-β-treated MMCs (Fig. 4e) . Quantification of the percentage of cells with cytoplasmic FoxO3a (Fig. 4f ) confirms that these miRNAs induced significant nuclear to cytoplasmic translocation of FoxO3a in serum-depleted MMCs, similarly to TGF-β, whereas inhibitors of these miRNAs attenuated TGF-β effects. Therefore, these miRNAs promote FoxO3a phosphorylation and cytoplasmic translocation by inhibiting Pten and activating Akt.
To test whether this miRNA circuit functionally inhibits FoxO3a transcriptional activity, MMCs were transfected with a luciferase reporter containing forkhead-response elements (pFRE-Luc) 4 along with the miRNAs. Both miR-192 and miR-216a + miR-217 inhibited luciferase activity of the reporter, similarly to TGF-β ( Fig. 5a ). Inhibitors of these miRNAs could override the TGF-β-induced reduction in luciferase activity (Fig. 5b) . By downregulating Pten and activating Akt, this miRNA circuit could inhibit FoxO3a function. The expression of the pro-apoptotic gene Bim, a FoxO3a target, was inhibited by miR-192 and miR-216a + miR-217 as well as TGF-β, whereas inhibitors of these miRNAs reversed the effects of TGF-β ( Fig. 5c ). Moreover, miR-192, miR-216a + miR-217 and TGF-β prevented serum-depletion-induced MMC apoptosis, and the TGF-β effect was reversed by miR inhibitors (Fig. 5d ). Therefore, similarly to TGF-β, these miRNAs promote MMC survival by downregulating Bim through Akt activation (due to Pten reduction) and subsequent FoxO3a phosphorylation. Expression of the antioxidant gene MnSOD (manganese superoxide dismutase), another FoxO3a target 4 , was also inhibited by TGF-β, miR-192 and miR-216a + miR-217 mimics, whereas miRNA inhibitors restored its expression ( Supplementary Information, Fig. S5a ), suggesting that this miRNA circuit may also upregulate oxidant stress in MMCs through FoxO3a phosphorylation.
Finally, we evaluated glomerular mesangial cell hypertrophy, a major feature of diabetic nephropathy and a downstream consequence of Akt activation 2,5,6,11,28 . TGF-β significantly increased protein levels (Fig. 5e ), confirming that it induces MMC hypertrophy. The miR-192 and miR-216a + miR-217 mimics similarly induced hypertrophy in serum-depleted glomerular mesangial cells, whereas inhibitors of these miRNAs attenuated TGF-β effects (Fig. 5e ), suggesting that this miRNA circuit mediates TGF-β-induced MMCs hypertrophy. The Akt downstream proteins mTOR and GSK3β also regulate protein synthesis and hypertrophy 6, 28 . Our results from miRNA mimics and inhibitors on mTOR and GSK3β phosphorylation ( Fig. 4a-d) further support a role for these miRNAs in TGF-β-induced glomerular mesangial cell hypertrophy. As FoxO3a is implicated in the regulation of autophagy genes 29 , these miRNAs might also promote hypertrophy through reducing autophagy.
Notably, cyclin-dependent kinase inhibitor p21-mediated cell-cycle arrest, but not apoptosis, of cancer cells induced by miR-192 through the p53 pathway was reported recently 30 , and miR-192 was found to activate the promoter of the anti-apoptotic Survivin gene 31 . Our results show that miR-192 also activates Akt and protects cells from apoptosis (Fig. 5d ). Therefore, miR-192 probably induces cell-cycle arrest but not apoptosis. Since p21-mediated cell-cycle arrest is related to glomerular mesangial cell hypertrophy 11 , miR-192 might also promote glomerular hypertrophy by activating p21 and p53. Further studies are needed to verify this.
In summary, miR-216a and miR-217 are co-expressed with RP23 and downregulate the same target (PTEN), illustrating an efficient way to control target genes under certain disease states ( Supplementary  Information, Fig. S6 ). Co-expression of miR-216a and miR-217 in the pancreas (high in acinar but low in islets) 24, 32 and expression of PTEN (high in islets but low in acinar) 33 support such regulation. Our current results also demonstrate a new mechanism for Akt activation by TGF-β through miR-216a and miR-217-mediated PTEN downregulation, controlled by upstream miR-192 ( Fig. 5f ). Akt activation by this miRNA circuit produced biological effects in MMCs including ECM gene expression, cell survival and hypertrophy, all classic features of diabetic nephropathy . Since the E-box regulators, PTEN and Akt, also have key roles in cancer development and insulin signalling 12, 13, 23 , miR-192, miR-216a and miR-217 may also regulate not only kidney disorders, but also cancer and metabolic diseases. Inhibitors of these miRNAs, their host non-coding RNAs or promoters could therefore serve as new therapeutic modalities for such diseases.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturecellbiology/. Immunohistochemistry. Immunostaining of renal cortical sections was performed as reported previously 4 using antibodies to PTEN and quantified with Image-Pro Plus 5.1 software (Media Cybernetics, Inc.).
Target prediction and genomic structure of human and mouse miRNAs.
We used the online databases miRBase (http://microrna.sanger.ac.uk), TargetScan (http://www.targetscan.org), microRNA.org (http://www.microrna.org/microrna/ home.do), NCBI (http://www.ncbi.nlm.nih.gov), Blat (http://genome.ucsc.edu/ cgi-bin/hgBlat) and Ensembl (http://www.ensembl.org) for target prediction and analysis of the genomic structure of human and mouse miRNAs. RP23-298H6.1-001 . The promoter regions of RP23 were cloned by PCR using primers, 5'-AAGG ag atctTCA-CTTCA TGAACAAACTGCCTT-3' and 5'-CTTGaagcttCA TCACTGG-AAT G T TATTA A GTCAAG-3' for the proximal -0.5 kb fragment, 5'-CT A ctc ga GGCTACCCTGCATCCTTTTCTAG-3' and 5'-CTTGaag c ttCATCA-CTGGAATGTTATTAAGTCAAG-3' for the proximal -2.7 kb fragment, 5'-CCAAGCTAGCCAGATCATAATAGTGAGGTTTGG-3' and 5'-CTTGaa-gcttCAT CACTGGAATGTTATTAAGTCAAG-3' for the proximal -3.5 kb fragment, 5'-CCCAGCTAGCCAGATCAAAAGCAGCTTGGG-3' and 5'-CTTGaagc ttCA TCACT GGAATGTTATTAAGTCAAG-3' for the proximal -4.8 kb fragment, 5'-CCA AGCTAGCCAGATCATAATAGTGAGGTTTGG-3' and 5'-CAC TCGA GTCTGATTGGAGTTACCAGTG-3' for the -3.5-2.7 kb fragment, and 5'-CCCAGCTAGCCAGATCAAAAGCAGCTTGGG-3' and 5'-GCACTCG-AGTCTGTGTGCAGGCTAAGTGC-3' for the -4.8-3.5 kb fragment. The entire -4.8 k, -3.5 k, -2.7 k and proximal regions were cloned into pGL4. The -3.5 -2.7 kb and -4.8-3.5 kb fragments were cloned into the pGL3-promoter (Promega). Reporter with 2× E-boxes was made by digestion of HpaI site. 1×E-box was generated by PCR using a primer, 5'-TGGGAGATCTTGGCACGTGCCTTCAATCCCA-3' (E-box underlined) and -2.7 k reverse primer, and cloned into the pGL3 promoter. The mutant E-box construct was generated by PCR using primers, 5'-TGGCTAGCGCCTTCAATCCCA-3' (mutant E-box is underlined) and -2.7 k reverse primer, and cloned into the pGL3P.
Cloning of the promoter regions of

Plasmids and 3'-UTR reporters. Full-length 3'UTR of mouse
Pten was amplified using primers, 5'-CATGCTCGAGCTTATCAAGAGGGATAAAATACCATG-3'and 5 ' -C ATG C G G C C G C C AC AG G A AG G TAT T TC TAG TC T TATG -3 ' . The PCR fragment was digested with XhoI and NotI and cloned into psi-Check2 (Promega). The shorter 1.4 kb fragment of Pten 3'UTR (which includes the miR-216a and miR-217 sites) was amplified using primers, 5'-CATGCTCGAGCTTATCAAGAGGGATAAAATACCATG-3' and 5'-GTTGCGGCCGCTTTACTGCAACTCTAATTTCTTTTTTAAC-3'. The miR-216a site mutant in the 1.4 kb construct was made by Quick Change site-directed mutagenesis (Stratagene) using primers, 5'-TTCACA-GGAAATTTCAACTCCGAATTCAACAGTAA-3' and 5'-TTACTG-TTG AATTCGGAGTTGAAATTTCCTGTGAA-3'. Substituted bases are underlined. The miR-217 site mutant was amplified using primers, 5'-CATGCTC-GAGCTTATCAAGAGGG ATAAAATACCATG-3' and 5'-GTTGC GG-CCGCTTGAGATCTACT CTAATTTCTTTTTTAAC-3'. Substituted bases are underlined. Sequences of all the inserts were confirmed by sequence analysis. For Pten 3'UTR minimum target site reporters, NotI site-tagged potential target sequences in the 3'UTR of mouse Pten (for the miR-216a site, sense, 5'-GG CCT TCACAGGAAATTTCAACTTGAGATTC-3'; antisense, 5'-GGCCGAATCTCAAGTTGAAATTTCCTGTGAA-3', for the miR-217 site, sense, 5'-GGCCAAAAGAAATTAGAGTTGCAGTAA-3'; antisense, 5'-ggccT-TACTGCAACTCTAATTTCTTTT-3') were cloned into NotI site of psiCheck2 (Promega). A plasmid containing a sense Pten-3'UTR sequence was used as reporter (psiCheck2mPten-3'UTR-S) and the plasmid containing the 3'UTR sequence in the anti-sense orientation was used as negative control (psiCheck2mPten-3'UTR-AS). The plasmid expressing FoxO3a-GFP and the luciferase reporter plasmid with pFRE-Luc were described previously 4 .
Luciferase assays. MMCs were transfected with luciferase reporter plasmids and/ or small RNAs using XtremeGENE (Roche) in 24-well-plates and treated with TGF-β as reported previously 3 . After 24 h, luciferase activity was measured as described previously 3 . For miRNA and shRNA experiments, cells were treated for 48 h. Glomerular mesangial cells were also transfected with plasmids and/ or small RNAs using Nucleofector (Amaxa Biosystems). Basic Nucleofector Kit for Primary Smooth Muscle Cells (Amaxa) was used. Five programs (A33, D33, P13, P24 and U25) were tested to examine the transfection efficiency of glomerular mesangial cells with pmaxGFP (Amaxa). Program U25 resulted in highest efficiency (~60%) and was used in subsequent experiments ( Supplementary  Information, Fig. S5b ). miRNA mimics and inhibitor oligonucleotides. miRNA mimics, negative control #1 mimics, miRNA inhibitors, and negative control #1 inhibitors were obtained from Dharmacon. Sequences of mimics and inhibitors are based on Sanger miRBase (http://microrna.sanger.ac.uk). LNA-modified anti-miRNAs were obtained from Exiqon and Integrated DNA Technologies, Inc. LNA-anti-miR-192: 21mer, 5'-gGctGtcAatTcaTagGtcAg-3' (uppercase: LNA; lowercase: DNA, full phosphorothioate) or control LNA-anti-miR-239b; 21mer, 5'-cAg-tActTttGtgTagTacAa-3' were subcutaneously injected (2.5 mg kg -1 ) into normal C57BL/6 mice and renal cortical tissues were harvested 6 h later.
In situ hybridization. To detect LNA-anti-miR-192 accumulation in vivo, in situ hybridization was performed as described previously 27 . Briefly, frozen kidney cortex sections from LNA-anti-miR-192-injected and saline control mice (n = 3 per group) were fixed in paraformaldehyde (3% for 10 min at room temperature) followed by rinsing in PBS. Slides were pre-hybridized (at 48 °C for 30 min) in hybridization solution (50% formamide, 5× SSC, 500 μg ml -1 yeast tRNA and 1×Denhardt's solution), and then hybridized (at 48 °C for 5 min) with a Texas Red-labeled LNA-modified oligonucleotide probe complementary to LNA-anti-miR-192 (21mer, 5'-TexasRed-ctgAccTatGaaTtgAcaGcc-3' (Exiqon) followed by post-hybridization wash (3 × 10 min, 55 °C) in 0.1× SSC. Slides were then stained with DAPI (4,6-diamidino-2-phenylindole), mounted and analysed using a fluorescence microscope. ESTs (BG807939 and BG805565) were identified just after the miR-216a precursor sequence which could be cropped fragments of the precursor miR-216a RNA. CAGA repeats and potential E-box clusters were found in the -5~-2kb upstream region of mouse RP23. b, Tfe3 overexpression in MMC significantly increased promoter-Luc activity of RP23-3.5-2.7k-luc (n=4). Tfe3 and its shRNA expression vectors were previously described 23 . c, Cotransfection with Tfe3 shRNAs (two constructs targeting different sites, 832 and 1014) significantly decreased RP23-3.5-2.7k-luc activity (n=4). d, ChIP analysis showing significant increase in Tfe3 occupancy at the RP23-3.5-2.7k region by 6h of TGF-β treatment (n=3). e. ChIP analysis showing decreased occupancy of Zeb1 at RP23-3.5-2.7k region (10% of control) 24 h after TGF-β treatment (n=3). ChIPs were performed with antibodies against Zeb1 (SantaCruz, Santa Cruz, CA), Tfe3 (BD Bioscience, Franklin Lakes, NJ), or IgG (negative control). ChIP-enriched DNA was purified and utilized as template for real time qPCRs using primers, 5'-TGGGAGATCTTGGCACGTGCCTTCAATCCCA-3' (E-box is underlined) and 5'-CACTCGAGTCTGATTGGAGTTACCAGTG-3'. f, Genomic structures of human miR-216a, miR-217 and a non-coding RNA (DA732292) on chromosome 2. CAGA repeats and potential E-box clusters are found in the -7.3~-6.5kb upstream region of human DA732292 genes. g,h, The -7.3-6.5k upstream region of human DA732292 (DA73-7.3-6.5-luc) was amplified using primers, 5'-CTAggtacCAGGTGGGGCAGGGGATTGTAG-3' and 5'-AAGcccgggCAGCTGGCCTACTAATCTACATACCCTT-3' and cloned into pGL3P. This Luc reporter responded significantly to TGF-β in MMC (g) and to miR-192 Mimic in human HEK293 cells (h) (n=4), similar to mouse RP23 promoter. Bar graph data expressed as mean and s.e.m. i, Schematic model of RP23 promoter regulation. TGF-β increases RP23 gene (also miR-216a and miR-217) expression by inducing miR-192 that targets and inhibits Zeb2 (E-box repressor), and also by inhibiting Zeb1 (another E-box repressor) (via as yet unknown mechanisms) and upregulating Tfe3 (E-box activator). Therefore, miR-216a and miR-217 may be induced by TGF-β via de-repression at the upstream E-boxes of the host RP23 gene. This leads to significant decrease in Pten protein levels in MMC treated with TGF-β ( Fig. 2e ). However, no decrease in mRNA levels of Pten was observed ( Supplementary Fig. S1h,p) . Therefore, Pten protein levels are most likely reduced via translational inhibition by TGF-β and these miRs. This illustrates an efficient manner by which target genes can be controlled in response to TGF-β. 
